SPY335.57+1.00 0.30%
DIA278.14+3.52 1.28%
IXIC10,968.36-42.63 -0.39%

Spectrum Pharmaceuticals shares are trading higher after the company announced results in HER2 Exon20 Insertion Mutations from Cohort 2 of the Poziotinib ZENITH20 trial met the pre-specified primary endpoint.

Benzinga · -